(New York Times, Dec. 13, 2023)
The justices announced that they would hear a case challenging the FDA’s approval of the commonly used pill, mifepristone.
The move sets up a high-stakes fight over the drug, , that could sharply curtail access to the medication, even in states where abortion remains legal. It could also have implications for the regulatory authority of the FDA, which approved the pill more than two decades ago.